1·Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
医生，刚才您所阅读的简介其实就是(吉非替尼)易瑞沙。
2·Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
3·Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.
背景：此前的无对照研究显示肺癌一线治疗联合吉非替尼治疗非小细胞肺癌是有效的。
4·Objective: To synthesize gefitinib.
前言： 目的： 合成吉非替尼。